Clinical trial NCT04973657: A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN
Official title: Phase 1b, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, PD and PK of VK0214, in Subjects With the Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
Keywords: AMN, XALD
Lead sponsor: Viking Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2021-07-22
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: OTHER

Brief summary: Subjects will be administered multiple doses of VK0214 in a cohort dose escalation process. A total of up to 36 subjects will be enrolled in the study, into one of three dose cohorts. For each cohort, up to 12 subjects will be randomized to receive VK0214 or placebo in a 3:1 ratio so that there will be a total of up to 9 subjects for each of the active doses and up to 3 subjects dosed with placebo in each cohort.

Detailed description: The first part of VK0214-102 will include the first 2 dose cohorts and placebo, which will be dosed in parallel (up to N=24). The first 2 doses used in these cohorts will be 20 mg QD and 40 mg QD for 28 days. A Dose Level Review Team (DLRT) meeting will be held at the end of the first 2 parallel doses.

The DLRT will review safety, tolerability, and preliminary efficacy data from cohort 1 and 2. If the data analyzed show that the first 2 doses are safe and well tolerated the DLRT may make a recommendation for proceeding to commence dosing in the third dose cohort.

Based upon outcomes in Cohorts 1 and 2, the sponsor may decide to include a third dose cohort. Before screening may be initiated in Cohort 3, data to support dosing in this cohort will be submitted to the FDA, together with the amended protocol and the dosing recommendation of the DLRT.

Eligibility criteria: Inclusion Criteria:

* Provide a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study and is willing and able to participate.
* Have diagnosis of X-linked adrenoleukodystrophy (X-ALD) by genetic testing and elevated VLCFAs.
* Present clinical features of AMN, or adrenal insufficiency.
* Subjects must be 18 years of age and older.

Exclusion Criteria:

* Have the cerebral form of X-ALD, based on medical records, or based on MRI performed within the last 12 months or MRI at screening
* Have been treated with any drug targeting TRβ or with any drug being tested as therapy for X-ALD AMN form within the past 30 days before screening
* History or presence of clinically significant acute or unstable hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological or oncological that in the opinion of the investigator would pose a significant risk for the subject
* Subject has untreated primary adrenal insufficiency based on morning plasma cortisol and ACTH at screening
* Lorenzo's Oil. Currently taking Lorenzo's Oil or erucic acid containing product, or other lipid lowering agent known to effect VLCFA levels

Primary outcomes:
measure: Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)
timeFrame: 28 days
Secondary outcomes:
measure: Evaluate the Pharmacokinetics of VK0214
timeFrame: 28 days
Other outcomes:
measure: Evaluate plasma VLCFAs changes
timeFrame: 28 days
Locations:
city: Palo Alto
country: United States
facility: Viking Clinical Site 203
state: California
city: Gainesville
country: United States
facility: Viking Clinical Site 207
state: Florida
city: Baltimore
country: United States
facility: Viking Clinical Site 201
state: Maryland
city: Seattle
country: United States
facility: Viking Clinical Site 205
state: Washington
city: Bordeaux
country: France
facility: Viking Clinical Site 214
city: Montpellier
country: France
facility: Viking Clinical Site 215
city: Leipzig
country: Germany
facility: Viking Clinical Site 209
city: Milano
country: Italy
facility: Viking Clinical Site 210
city: London
country: United Kingdom
facility: Viking Clinical Site 212
Study officials:
References: